RIGL(RIGL)
RIGL
ANALYST COVERAGE14 analysts
BUY
▲ +31.0%upside to target
L $2.00
Med $38.00consensus
H $42.00PRICE
Prev Close
31.92
Open
31.92
Day Range28.63 – 32.80
28.63
32.80
52W Range18.14 – 52.24
18.14
52.24
32% of range
VOLUME & SIZE
Avg Volume
397.9K
FUNDAMENTALS
P/E Ratio
1.5x
Value territory
EPS (TTM)
—
Div Yield
No dividend
Beta
1.47
Market-like
TECHNICAL
RSI (14)
42
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 18
DEx-Dividend
In 89 days
Aug 14
PDividend Pay
In 115 days
Sep 9
Key MetricsTTM
Market Cap$536.75M
Revenue TTM$299.77M
Net Income TTM$364.23M
Free Cash Flow$79.27M
Gross Margin93.4%
Operating Margin41.6%
Net Margin121.5%
Return on Equity147.0%
Return on Assets72.2%
Debt / Equity0.11
Current Ratio2.62
EPS TTM$19.78
RIGL News
About
rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Raul Rodriguez
Website
Lisa RojkjaerExecutive Vice President & Chief Medical Officer
David A. SantosExecutive Vice President & Chief Commercial Officer
Dean L. SchornoExecutive Vice President & Chief Financial Officer
Raul R. RodriguezPresident, Chief Executive Officer & Director
Julie PatelSenior Vice President of Human Resources
Raymond J. FureyExecutive Vice President, Chief Compliance Officer, General Counsel & Corporate Secretary
Joseph LasagaExecutive Vice President & Chief Business Officer
Tarek SallamVice President of Marketing